TY - JOUR
T1 - Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
T2 - A Systematic Literature Review and Network Meta-analysis
AU - Facon, Thierry
AU - San-Miguel, Jesús
AU - Dimopoulos, Meletios A.
AU - Mateos, Maria Victoria
AU - Cavo, Michele
AU - van Beekhuizen, Sophie
AU - Yuan, Zijiao
AU - Mendes, João
AU - Lam, Annette
AU - He, Jianming
AU - Ammann, Eric
AU - Kumar, Shaji
N1 - Funding Information:
The analysis was funded by Janssen Global Services, LLC. The journal’s rapid service and open access fees were funded by Janssen Global Services, LLC.
Funding Information:
Editorial and medical writing support was provided by Karen Pemberton, PhD, of Eloquent Scientific Solutions and was funded by Janssen Global Services, LLC.
Funding Information:
The analysis was funded by Janssen Global Services, LLC. The journal’s rapid service and open access fees were funded by Janssen Global Services, LLC. Editorial and medical writing support was provided by Karen Pemberton, PhD, of Eloquent Scientific Solutions and was funded by Janssen Global Services, LLC. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors contributed equally to the study design and data interpretation. SB performed the systematic literature search, data collection, and analysis. ZY updated the network meta-analysis. All authors contributed to writing the manuscript, approved the final version, decided to publish this report, and vouch for data accuracy and completeness. Thierry Facon served on advisory committees for Amgen, Celgene, Janssen, Karyopharm, Oncopeptides, Roche, Sanofi, and Takeda; and speakers’ bureaus for Celgene, Janssen, and Takeda. Jesús San-Miguel received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Roche, and Sanofi. Meletios A. Dimopoulos received honoraria from Amgen, BeiGene, Bristol-Myers Squibb, Janssen-Cilag, and Takeda and consulted for and/or served in an advisory role for Amgen, BeiGene, Bristol-Myers Squibb, Janssen-Cilag, and Takeda. Maria-Victoria Mateos received honoraria from Amgen, AbbVie, Adaptive Biotechnologies, Celgene, GlaxoSmithKline, Janssen-Cilag, Roche, and Takeda and served in a consulting and/or advisory role for Amgen, AbbVie, Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Regeneron, Roche/Genentech, and Takeda. Michele Cavo received honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Janssen and served in a consulting and/or advisory role for AbbVie, Amgen, Celgene, and Janssen. Sophie van Beekhuizen and Zijiao Yuan are employees of Ingress Health. Jianming He, Eric Ammann, Annette Lam, and João Mendes are employees of Janssen and may own company stock. Shaji Kumar received research funding from Takeda, Janssen, and Celgene and has consulted for Janssen and Celgene. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/5
Y1 - 2022/5
N2 - Introduction: Many treatment regimens have been evaluated in transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). The objective of this study was to compare the efficacy of relevant therapies for the treatment of TIE patients with NDMM. Methods: Progression-free survival (PFS) and overall survival (OS) from large randomised controlled trials (RCTs) evaluating different treatment options for TIE patients with NDMM were compared in a network meta-analysis (NMA). The NMA includes recent primary and long-term OS readouts from SWOG S0777, ENDURANCE, MAIA, and ALCYONE. Relevant trials were identified through a systematic literature review. Relative efficacy measures (i.e., hazard ratios [HRs] for PFS and OS) were extracted and synthesised in random-effects NMAs. Results: A total of 122 publications describing 45 unique RCTs was identified. Continuous lenalidomide/dexamethasone (Rd) was selected as the referent comparator. Daratumumab-containing treatments (daratumumab/lenalidomide/dexamethasone [D-Rd], daratumumab/bortezomib/melphalan/prednisone [D-VMP]) and bortezomib/lenalidomide/dexamethasone (VRd) had the highest probabilities of being more effective than Rd continuous for PFS (HR: D-Rd, 0.53; D-VMP, 0.57, VRd, 0.77) and OS (HR: D-Rd, 0.68; VRd, 0.77, D-VMP, 0.78). D-Rd had the highest chance of being ranked as the most effective treatment with respect to PFS and OS. Results using a smaller network focusing on only those regimens that are relevant in Europe were consistent with the primary analysis. Conclusions: These comparative effectiveness data may help inform treatment selection in TIE patients with NDMM.
AB - Introduction: Many treatment regimens have been evaluated in transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). The objective of this study was to compare the efficacy of relevant therapies for the treatment of TIE patients with NDMM. Methods: Progression-free survival (PFS) and overall survival (OS) from large randomised controlled trials (RCTs) evaluating different treatment options for TIE patients with NDMM were compared in a network meta-analysis (NMA). The NMA includes recent primary and long-term OS readouts from SWOG S0777, ENDURANCE, MAIA, and ALCYONE. Relevant trials were identified through a systematic literature review. Relative efficacy measures (i.e., hazard ratios [HRs] for PFS and OS) were extracted and synthesised in random-effects NMAs. Results: A total of 122 publications describing 45 unique RCTs was identified. Continuous lenalidomide/dexamethasone (Rd) was selected as the referent comparator. Daratumumab-containing treatments (daratumumab/lenalidomide/dexamethasone [D-Rd], daratumumab/bortezomib/melphalan/prednisone [D-VMP]) and bortezomib/lenalidomide/dexamethasone (VRd) had the highest probabilities of being more effective than Rd continuous for PFS (HR: D-Rd, 0.53; D-VMP, 0.57, VRd, 0.77) and OS (HR: D-Rd, 0.68; VRd, 0.77, D-VMP, 0.78). D-Rd had the highest chance of being ranked as the most effective treatment with respect to PFS and OS. Results using a smaller network focusing on only those regimens that are relevant in Europe were consistent with the primary analysis. Conclusions: These comparative effectiveness data may help inform treatment selection in TIE patients with NDMM.
KW - Multiple myeloma
KW - Network meta-analysis
KW - Progression-free survival
KW - Transplant ineligible
UR - http://www.scopus.com/inward/record.url?scp=85125635445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125635445&partnerID=8YFLogxK
U2 - 10.1007/s12325-022-02083-8
DO - 10.1007/s12325-022-02083-8
M3 - Article
C2 - 35246820
AN - SCOPUS:85125635445
SN - 0741-238X
VL - 39
SP - 1976
EP - 1992
JO - Advances in Therapy
JF - Advances in Therapy
IS - 5
ER -